Accuracy of fibronectin tests for the prediction of pre-eclampsia: a systematic review

European Journal of Obstetrics and Gynecology and Reproductive Biology

Volumn 133, Issue 1, 2007, Pages 12-19

  Leeflang, M M G ^a   Cnossen, J S ^a   van der Post, J A M ^a   Mol, B W J ^a   Khan, K S ^b   ter Riet, G ^a,c  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b BIRMINGHAM WOMEN S HOSPITAL   (United Kingdom)

^c UNIVERSITY OF ZURICH   (Switzerland)

Author keywords

Fetal fibronectin; Fibronectin; Pre eclampsia; Prediction; Sensitivity and specificity

Indexed keywords

FIBRONECTIN;

CALCULATION; DATA ANALYSIS; DATA EXTRACTION; DATA SYNTHESIS; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST; DISEASE MARKER; GESTATION PERIOD; HUMAN; INCIDENCE; PREDICTION; PREECLAMPSIA; PREGNANT WOMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; QUALITATIVE ANALYSIS; QUALITY CONTROL; REVIEW; ROC CURVE; SENSITIVITY ANALYSIS; SENSITIVITY AND SPECIFICITY; SYSTEMATIC REVIEW;

EID: 34250740267     PISSN: 03012115     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejogrb.2007.01.003     Document Type: Review

References (48)

1. Report of the National High Blood Pressure Education Program Working Group on high blood pressure in pregnancy. Am J Obstet Gynecol 2000;183(1):S1-22.
2. Cooper G.M., Lewis G., and Neilson J. Confidential enquiries into maternal deaths, 1997-1999. Br J Anaesth 89 3 (2002) 369-372
3. Montan S., Sjoberg N.O., and Svenningsen N. Hypertension in pregnancy - fetal and infant outcome - a cohort study. Clin Exp Hypertens Part B Hypertens Pregnancy 6 2 (1987) 337-348
4. MacGillivray I. Pre-eclampsia. The hypertensive disease of pregnancy (1983), WB Saunders Company Ltd., London
5. Chesley L.C. History and epidemiology of pre-eclampsia-eclampsia. Clin Obstet Gynecol 27 4 (1984) 801-820
6. Turnbull A.C. Maternal mortality and present trends. In: Sharp F., and Symmonds E.M. (Eds). Hypertension in pregnancy (1987), Perinatology Press, Ithaca, New York 135-150
7. Broughton P.F., Crowther C., de Swiet M., et al. Where next for prophylaxis against pre-eclampsia?. Br J Obstet Gynaecol 103 7 (1996) 603-607
8. Coomarasamy A., Papaioannou S., Gee H., and Khan K.S. Aspirin for the prevention of pre-eclampsia in women with abnormal uterine artery Doppler: a meta-analysis. Obstet Gynecol 98 5, Part 1 (2001) 861-866
9. Montan S. Drugs used in hypertensive diseases in pregnancy. Curr Opin Obstet Gynecol 16 2 (2004) 111-115
10. Duley L., Henderson-Smart D.J., Knight M., and King J.F. Antiplatelet agents for preventing pre-eclampsia and its complications. Cochrane Database Syst Rev 1 (2004) CD004659
11. Roberts J.M., and Redman C.W.G. Pre-eclampsia: more than pregnancy-induced hypertension. Lancet 341 8858 (1993)
12. Ascarelli M.H., and Morrison J.C. Use of fetal fibronectin in clinical practice. Obstet Gynecol Surv 52 Suppl. 4 (1997) S1-S12
13. Dunn P.A., and Feinberg R.F. Oncofetal fibronectin: new insight into the physiology of implantation and labor. J Obstet Gynecol Neonatal Nurs 25 9 (1996) 753-757
14. Koenn M.E. Fetal fibronectin. Clin Lab Sci 15 2 (2002) 96-98 115
15. Honest H., Bachmann L.M., Gupta J.K., Kleijnen J., and Khan K.S. Accuracy of cervicovaginal fetal fibronectin test in predicting risk of spontaneous preterm birth: systematic review. BMJ 325 7359 (2002) 301
16. Leitich H., and Kaider A. Fetal fibronectin-how useful is it in the prediction of preterm birth?. BJOG 110 Suppl. 20 (2003) 66-70
17. Conde-Agudelo A., Lede R., and Belizan J. Evaluation of methods used in the prediction of hypertensive disorders of pregnancy. Obstet Gynecol Surv 49 3 (1994) 210-222
18. Conde-Agudelo A., Villar J., and Lindheimer M. World Health Organization systematic review of screening tests for pre-eclampsia. Obstet Gynecol 104 6 (2004) 1367-1391
19. Humpfner A., Hummel S., Heidegger H., Getz B., Deuber H.J., and Schulz W. Classes of hypertension in pregnancy-diagnostic possibilities of prediction and differentiation. Nieren und Hochdruckkrankheiten (German) 23 1 (1994) 16-32
20. Magann E.F., and Martin Jr. J.N. The laboratory evaluation of hypertensive gravidas. Obstet Gynecol Surv 50 2 (1995)
21. Myatt L., and Miodovnik M. Prediction of pre-eclampsia. Semin Perinatol 23 1 (1999) 45-57
22. O'Brien W.F. Predicting pre-eclampsia. Obstet Gynecol 75 3 Pt 1 (1990) 445-452
23. Steinhard J., and Klockenbusch W. Pregnancy-induced hypertonia and pre-eclampsia-risk factors and prediction possibilities. Gynakologe 32 10 (1999)
24. Visser W., and Wallenburg H.C. Prediction and prevention of pregnancy-induced hypertensive disorders. Baillieres Best Pract Res Clin Obstet Gynaecol 13 1 (1999) 131-156
25. Young P.F., Singh P., and O'Brien P.M.S. Screening for pregnancy-induced hypertension. Contemp Rev Obstet Gynaecol 6 4 (1994) 189-194
26. Zygmunt M., Lang U., and Munstedt K. Early prediction of pre-eclampsia: a short review. Gynakologe 35 7 (2002)
27. Cnossen J.S. World Health Organization systematic review of screening tests for pre-eclampsia. Obstet Gynecol 105 5, Part 1 (2005) 1151-1152 [Letter]
28. Bachmann L.M., Coray R., Estermann P., and ter Riet G. Identifying diagnostic studies in MEDLINE: reducing the number needed to read. J Am Med Inform Assoc 9 6 (2002) 653-658
29. Haynes R.B., and Wilczynski N.L. Optimal search strategies for retrieving scientifically strong studies of diagnosis from Medline: analytical survey. BMJ 328 7447 (2004) 1040
30. Jaeschke R., Guyatt G., and Sackett D.L. Users' guides to the medical literature. III. How to use an article about a diagnostic test. A. Are the results of the study valid? Evidence-Based Medicine Working Group. JAMA 271 5 (1994) 389-391
31. Lijmer J.G., Mol B.W., Heisterkamp S., et al. Empirical evidence of design-related bias in studies of diagnostic tests. JAMA 282 11 (1999) 1061-1066
32. Whiting P., Rutjes A.W., Reitsma J.B., Glas A.S., Bossuyt P.M., and Kleijnen J. Sources of variation and bias in studies of diagnostic accuracy: a systematic review. Ann Intern Med 140 3 (2004) 189-202
33. Whiting P., Rutjes A.W., Reitsma J.B., Bossuyt P.M., and Kleijnen J. The development of QUADAS: a tool for the quality assessment of studies of diagnostic accuracy included in systematic reviews. BMC Med Res Methodol 3 1 (2003) 25
34. Halligan A., Bonnar J., Sheppard B., Darling M., and Walshe J. Haemostatic, fibrinolytic and endothelial variables in normal pregnancies and pre-eclampsia. Br J Obstet Gynaecol 101 6 (1994) 488-492
35. Islami D., Shoukir Y., Dupont P., Campana A., and Bischof P. Is cellular fibronectin a biological marker for pre-eclampsia?. Eur J Obstet Gynecol Reprod Biol 97 1 (2001) 40-45
36. Jones I., Cowley D., Andersen M., Vacca A., and Voroteliak V. Fibronectin as a predictor of pre-eclampsia: a pilot study. Aust N Z J Obstet Gynaecol 36 1 (1996) 1-3
37. Ostlund E., Hansson L.O., and Bremme K. Fibronectin is a marker for organ involvement and may reflect the severity of pre-eclampsia. Hypertens Pregnancy 20 1 (2001) 79-87
38. Paarlberg K.M., de Jong C.L., van Geijn H.P., van Kamp G.J., Heinen A.G., and Dekker G.A. Total plasma fibronectin as a marker of pregnancy-induced hypertensive disorders: a longitudinal study. Obstet Gynecol 91 3 (1998) 383-388
39. Soltan M.H., Ismail Z.A., Kafafi S.M., Abdulla K.A., and Sammour M.B. Values of certain clinical and biochemical tests for prediction of pre-eclampsia. Ann Saudi Med 16 3 (1996) 280-284
40. Sud S.S., Gupta I., Dhaliwal L.K., Kaur B., and Ganguly N.K. Serial plasma fibronectin levels in pre-eclamptic and normotensive women. Int J Gynaecol Obstet 66 2 (1999) 123-128
41. Madazli R., Kuseyrioglu B., Uzun H., Uludag S., and Ocak V. Prediction of preeclampsia with maternal mid-trimester placental growth factor, activin A, fibronectin and uterine artery Doppler velocimetry. Int J Gynaecol Obstet 89 3 (2005 Jun) 251-257
42. Chavarria M.E., Lara-Gonzalez L., Gonzalez-Gleason A., Sojo I., and Reyes A. Maternal plasma cellular fibronectin concentrations in normal and preeclamptic pregnancies: a longitudinal study for early prediction of pre-eclampsia. Am J Obstet Gynecol 187 3 (2002) 595-601
43. Friedman S.A., de Groot C.J., Taylor R.N., and Roberts J.M. Circulating concentrations of fetal fibronectin do not reflect reduced trophoblastic invasion in preeclamptic pregnancies. Am J Obstet Gynecol 167 2 (1992) 496-497
44. Lockwood C.J., and Peters J.H. Increased plasma levels of ED1+ cellular fibronectin precede the clinical signs of pre-eclampsia. Am J Obstet Gynecol 162 2 (1990) 358-362
45. Taylor R.N., Crombleholme W.R., Friedman S.A., Jones L.A., Casal D.C., and Roberts J.M. High plasma cellular fibronectin levels correlate with biochemical and clinical features of pre-eclampsia but cannot be attributed to hypertension alone. Am J Obstet Gynecol 165 4 I (1991)
46. Zhang J., and Schisterman E.F. Maternal plasma cellular fibronectin for early prediction of pre-eclampsia. Am J Obstet Gynecol 189 4 (2003) 1212
47. Bossuyt P.M., Reitsma J.B., Bruns D.E., et al. Towards complete and accurate reporting of studies of diagnostic accuracy: the STARD initiative. BMJ 326 7379 (2003) 41-44
48. Bachmann L.M., Ter Riet G., Clark T.J., Gupta J.K., and Khan K.S. Probability analysis for diagnosis of endometrial hyperplasia and cancer in postmenopausal bleeding: an approach for a rational diagnostic workup. Acta Obstet Gynecol Scand 82 6 (2003) 564-569